Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 14,245 shares, a decline of 50.6% from the July 30th total of 28,818 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 345,411 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CHGCY shares. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Chugai Pharmaceutical has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 0.7%

CHGCY traded up $0.16 during trading on Friday, reaching $21.82. 117,081 shares of the company were exchanged, compared to its average volume of 208,202. Chugai Pharmaceutical has a 52 week low of $20.43 and a 52 week high of $34.84. The firm has a 50 day moving average of $22.25 and a 200 day moving average of $25.43. The stock has a market cap of $71.82 billion, a P/E ratio of 23.72 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. As a group, analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.